NCT07032727View on ClinicalTrials.gov

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

PHASE2RecruitingINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

September 12, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2029

Conditions

Targeted TherapyIDH1-Mutated MalignanciesMutations

Interventions

DRUG

Olutasidenib

Given by po

DRUG

Cladribine (CLAD)

Given by IV

DRUG

Venetoclax

Given by po

DRUG

Gilteritinib

Given by po

DRUG

Ruxolitinib

Given by po

DRUG

Cytarabine

Given SQ

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Rigel Pharmaceuticals

All Listed Sponsors

collaborator

Rigel Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER